Although IDH1 mutation has dual effects, acting either as an oncogene or as a tumor suppressor gene in glioma [7, 33], patients with IDH mutation exhibited better prognosis than those with wild-type IDH1 [34, 35] (Supplementary Fig. S8). This evidence concerns the gene IDH1 and glioma.